Multifunctional therapeutic patch for gastrointestinal tract and manufacturing method thereof
A three-layer medical patch with an unrolling and adhesive design, protected by a magnetically actuated capsule, addresses delivery and adhesion challenges in gastrointestinal treatment, enabling precise and visualized therapy.
Patent Information
- Application Number
- KR1020230192137
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2023-12-27
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2043-12-27
AI Technical Summary
Existing gastrointestinal treatment technologies face challenges in delivering therapeutic agents to multiple lesion sites with precision, ensuring adhesion to curved surfaces, protecting patches from gastrointestinal fluids, and providing real-time visualization during treatment due to limitations in capsule endoscopy and microneedle delivery systems.
A multifunctional medical patch composed of three layers: an unrolling layer made of PEGDM, a guard layer of TEGDM, and a therapeutic layer with a mucosal adhesive material, designed to unfold and adhere to curved surfaces, protected by a magnetically actuated capsule, and equipped with an imaging module for visualization.
The patch effectively delivers medical agents to multiple sites, adheres strongly to gastrointestinal surfaces, and provides real-time imaging, enhancing treatment efficacy and precision.
Smart Images

Figure 112023145950643-PAT00001_ABST
Abstract
Description
Technology Field
[0001] The present invention relates to a multifunctional medical patch for the gastrointestinal tract and a method for manufacturing the same. Background Technology
[0002] The gastrointestinal tract presents a challenging environment for treatment due to its complex anatomical structure and physiological conditions. The tract is moistened with mucus, possesses a curved surface, and lesions can occur in various locations. To overcome these obstacles and facilitate treatment, research has been conducted on various therapeutic methods, including conventional endoscopy, capsule endoscopy, and the application of nanoparticles.
[0003] Among these, research on treatments using capsule endoscopy has primarily focused on this method due to its advantages, such as non-invasiveness, ease of surgery, and short recovery periods. For example, a capsule has been developed to deliver insulin-laden microneedles (MNs) to the gastrointestinal tract. While capsules offer a higher drug absorption rate than subcutaneous injections, there are limitations in delivering therapeutic agents to multiple lesion sites and ensuring precise delivery to the gastrointestinal tract because microneedles can only be delivered once at a specific pH level. Additionally, a magnetically actuated capsule was developed to deliver gelatin microneedle patches loaded with multiple drugs; this capsule could move rapidly and deliver the patches to the gastrointestinal tract using an external magnetic field. However, there are issues with reduced drug delivery efficiency due to weak adhesion between the patch and the intestinal surface, and the patch is not protected from substances present in the gastrointestinal tract because the capsule opening remains open. Furthermore, a technology has been developed to deliver multiple chitosan-catechol patches using a magnetically actuated capsule equipped with an open-close mechanism. These improved patches demonstrated enhanced adhesion to the intestinal surface compared to gelatin microneedle patches and were partially protected by a capsule during transport via an open-close mechanism. However, complete protection of the patch by a capsule with an opening-close mechanism is impossible due to the inflow of low-viscosity fluids within the gastrointestinal tract, and effective delivery to curved gastrointestinal surfaces is difficult because the patch is flat. Additionally, the absence of an imaging module in the patch delivery capsule makes gastrointestinal visualization during treatment impossible.
[0004] Therefore, to address these existing issues, the characteristics of the drug-loaded patch and the active patch delivery capsule must be improved. To achieve this, first, the gastrointestinal therapeutic patch must possess therapeutic capabilities and be delivered in close contact with gastrointestinal surfaces having various curvatures. Second, the active capsule must be actively actuated by an external magnetic field, capable of protecting the loaded patch even in a wet gastrointestinal environment, and able to actively deliver the patch to multiple target lesion sites. Finally, the capsule must integrate an imaging module to observe the inside of the gastrointestinal tract, identify target lesions, and deliver the patch.
[0005] However, technology incorporating these improvements has not yet been developed. Prior art literature
[0006] Republic of Korea Published Patent 10-2023-0056347 The problem to be solved
[0007] Accordingly, the inventors developed a multifunctional medical patch for the gastrointestinal tract and a self-actuating capsule by considering improvements necessary for the characteristics of the drug delivery patch and the active capsule. The multifunctional medical patch for the gastrointestinal tract developed by the present invention is composed of an unrolling layer, a guard layer, and a medical layer. It has the characteristic of being able to be delivered by being loaded in multiple units onto a wired endoscope or a capsule endoscope due to its excellent rolling performance, and the characteristic of being able to be delivered by adhering closely to the curved inner surface of the gastrointestinal tract due to its unrolling performance. Furthermore, it has the characteristic of adhering sufficiently well to the surface of the gastrointestinal tract due to mucosal adhesion and can perform various medical functions by including a medical functional substance, thereby completing the present invention.
[0008] Accordingly, the objective of the present invention is to provide a multifunctional medical patch for the gastrointestinal tract composed of three layers: an unrolling layer, a guard layer, and a therapeutic layer, wherein the unrolling layer is composed of PEGDM (polyethylene glycol dimethacrylate) and causes swelling when in contact with liquid at the target site, the guard layer is located between the unrolling layer and the therapeutic layer and is composed of TEGDM (triethylene glycol dimethacrylate), and the therapeutic layer comprises a mucosal adhesive material and a medical material and adheres to the target site.
[0009] Another objective of the present invention is to provide a method for manufacturing a multifunctional medical patch for the gastrointestinal tract according to the present invention. means of solving the problem
[0010] To achieve the above-mentioned objective of the present invention, the present invention provides a multifunctional medical patch for the gastrointestinal tract composed of three layers: an unrolling layer, a guard layer, and a therapeutic layer, wherein the unrolling layer is composed of PEGDM (polyethylene glycol dimethacrylate) and causes swelling when in contact with liquid at the target site, the guard layer is located between the unrolling layer and the therapeutic layer and is composed of TEGDM (triethylene glycol dimethacrylate), and the therapeutic layer includes a mucosal adhesive material and a medical material and adheres to the target site.
[0011] In one embodiment of the present invention, the multifunctional medical patch for the gastrointestinal tract may be delivered to a target site within the gastrointestinal tract in a rolled form.
[0012] In one embodiment of the present invention, the rolled outer layer may be rolled to become a therapeutic layer.
[0013] In one embodiment of the present invention, the delivery may be such that one or more multifunctional medical patches for the gastrointestinal tract in a rolled form are mounted on a wired endoscope or a capsule endoscope and delivered to a target site.
[0014] In one embodiment of the present invention, the mucosal adhesive material may be one or more selected from the group consisting of chitosan, catechol, tannic acid, alginate, guar gum, xanthan gum, pectin, galactomannan, glucomannan, hyaluronic acid, glycosaminoglycans, gelatin, polyethylene glycol, polyethylene oxide, polyacrylic acid, polymethacrylic acid, polyvinylpyrrolidone, polyvinyl amine, and derivatives thereof.
[0015] In one embodiment of the present invention, the medical material may be one or more selected from the group consisting of anticancer agents, magnetic nanoparticles, hemostatic agents, tissue regeneration factors, biocompatible inks, fluorescent materials, reactive oxygen species sensing materials, and pH sensing materials.
[0016] In one embodiment of the present invention, the multifunctional medical patch for the gastrointestinal tract may be delivered to and adhered to a target site in a rolled form, and as the unrolling layer swells due to the liquid in the gastrointestinal tract, it fully unfolds to fit the curved surface of the target site, is strongly adhered by a mucosal adhesive material contained in the medical layer, and the medical material is released to the target site.
[0017] In addition, the present invention provides a method for manufacturing a multifunctional medical patch for the gastrointestinal tract, comprising: (1) a step of manufacturing a guard layer by irradiating a TEGDM (triethylene glycol dimethacrylate) solution with ultraviolet rays; (2) a step of manufacturing an unrolling layer on the guard layer manufactured in step (1) by dispensing a PEGDM (polyethylene glycol dimethacrylate) solution and irradiating ultraviolet rays; (3) a step of manufacturing a therapeutic layer on the guard layer by placing the two-layer structured guard layer and unrolling layer manufactured in step (2) into a resin mold with the guard layer facing upward, pouring a mixed solution of a mucosal adhesive material and a medical material over it, and then freeze-drying; and (4) a step of separating a multifunctional medical patch for the gastrointestinal tract composed of three layers, an unrolling layer, a guard layer, and a therapeutic layer, from the mold.
[0018] In one embodiment of the present invention, the multifunctional medical patch for the gastrointestinal tract separated from the mold in step (4) may further include the step of rolling the medical layer outward into a cylindrical shape, inserting it into a cylindrical resin mold, and heating it to manufacture a rolled multifunctional medical patch for the gastrointestinal tract.
[0019] In one embodiment of the present invention, the heating may be performed by using a heating gun at a temperature of 150°C to 250°C for 5 to 15 seconds.
[0020] In one embodiment of the present invention, the mucosal adhesive material may be one or more selected from the group consisting of chitosan, catechol, tannic acid, alginate, guar gum, xanthan gum, pectin, galactomannan, glucomannan, hyaluronic acid, glycosaminoglycans, gelatin, polyethylene glycol, polyethylene oxide, polyacrylic acid, polymethacrylic acid, polyvinylpyrrolidone, polyvinyl amine, and derivatives thereof.
[0021] In one embodiment of the present invention, the medical material may be one or more selected from the group consisting of anticancer agents, magnetic nanoparticles, hemostatic agents, tissue regeneration factors, biocompatible inks, fluorescent materials, reactive oxygen species sensing materials, and pH sensing materials. Effects of the invention
[0022] The multifunctional medical patch for the gastrointestinal tract according to the present invention can be delivered to a target site by loading multiple multifunctional medical patches for the gastrointestinal tract onto a wired endoscope or capsule endoscope due to its excellent rolling performance, and can be completely adhered to the inner surface of the curved gastrointestinal tract due to the characteristic that the unrolling layer unfolds when liquid is absorbed at the target site, and not only has excellent adhesion to the surface of the gastrointestinal tract due to the use of a mucosal adhesive material contained in the medical layer, but also can effectively perform various medical functions by including medical materials. Brief explanation of the drawing
[0023] FIG. 1 shows the structure of a multifunctional medical patch (TheraS) for the gastrointestinal tract according to the present invention, (a) showing the structure of the deployable TheraS of the present invention, (b) showing the unrolled and rolled states of TheraS, (c) showing a magnetically actuated capsule equipped with four TheraS, (d) showing the components of the magnetically actuated capsule, and (e~g) a schematic diagram showing the delivery and treatment process within the gastrointestinal tract using the magnetically actuated capsule equipped with TheraS of the present invention. FIG. 2 illustrates the manufacturing process of the gastrointestinal multifunctional medical patch (TheraS) of the present invention, showing (a) the manufacturing process of a two-layer structure by UV irradiation of TEGDM and PEGDM, (b) the sequential manufacturing process of a chitosan-catechol layer containing magnetic nanoparticles (MNPs) and an anticancer agent (DOX) on the two-layer structure, and (c) the manufacturing process of the rolled TheraS through heat treatment and the process of mounting it on a capsule device. Figure 3 shows the results of a characteristic analysis of the gastrointestinal multifunctional medical patch (TheraS) of the present invention, (a) and (b) are photographs of the unrolled and rolled states of TheraS observed with a digital camera, (c) and (d) are images of cross-sections of TheraS observed with SEM and a confocal microscope, (e) confirming the process of the unfolding of TheraS of the present invention on the surface of the small intestine, (f) showing the ATR-FT-IR spectra of the medical layer, guard layer, and unrolled layer of TheraS of the present invention, (g) showing the results of analyzing the adhesion strength (n=10) between the gelatin sheet and TheraS of the present invention on the surface of the small intestine or stomach, and (h) confirming the temperature change of TheraS of the present invention under AMF application at initial room temperature (RT: 16.5°C) and body temperature (BT: 37.0°C), where the shaded area indicates the cell death temperature and thermal tissue resection temperature when the initial temperature is BT (n=5). Figure 4 shows (a) the results of analyzing the release profile of a model drug (rhodamine) from TheraS after contact with the surface of the porcine small intestine, (b) the analysis of the extent of rhodamine release from TheraS over time on the surface of the porcine small intestine (n=5), and (c) the analysis of the extent of DOX drug release from TheraS with or without AMF application after contact with the porcine small intestine (n=5). FIG. 5 shows the initial and final states in a pig stomach before and after delivering four TheraS to a target site using (a) and (b) magnetic capsules, and (c) to (f) show photographs captured using a camera mounted on the capsule showing the delivery of TheraS of the present invention to a pig stomach. Figure 6 shows the results of the hemostatic performance analysis of TheraS of the present invention, including (a) an image of hemolyzed blood after a whole blood coagulation test in a 96-well plate, (b) the results of a comparative analysis of whole blood coagulation performance for control blood, a gelatin sheet, a gelatin-chitosan sheet, and TheraS of the present invention (n = 5), (c) confirmation of coagulated blood of each sample on the plate, and (d) an image confirming platelets attached to the gelatin sheet, the gelatin-chitosan sheet, and TheraS of the present invention by SEM analysis. Figure 7 confirms the in vitro therapeutic effect of TheraS of the present invention using HT-29 cells, (a) to (f) observe the survival of HT-29 cells after 24 hours in the control group, the TheraS (MNPs- and DOX-) treated group, the TheraS (DOX-) treated group, and the TheraS treated group according to whether AMF was applied and whether AMF was applied, respectively, and (g) shows the HT-29 cell survival rate as a CCK-8 analysis graph (n = 5). *p<0.005, **p<0.0005, ns p>0.05, and all scale bars are 500μm. In Fig. 8, (a) and (b) show areas of the porcine small intestine that underwent heat resection using TheraS under AMF, (c) and (d) show areas of the porcine stomach that underwent heat resection using TheraS under AMF, and (e) and (f) show H&E stained images of coagulated necrosis (CN) and normal tissue (NT) in the porcine small intestine and stomach after heat resection with TheraS under AMF. Specific details for implementing the invention
[0024] The present invention is characterized by providing a multifunctional medical patch for the gastrointestinal tract and a method for manufacturing the same.
[0025] Specifically, the multifunctional medical patch for the gastrointestinal tract according to the present invention is composed of three layers: an unrolling layer, a guard layer, and a therapeutic layer. The unrolling layer is composed of PEGDM (polyethylene glycol dimethacrylate) and causes swelling when in contact with liquid at the target site. The guard layer is located between the unrolling layer and the therapeutic layer and is composed of TEGDM (triethylene glycol dimethacrylate). The therapeutic layer includes a mucosal adhesive material and a medical material and is characterized by adhering to the target site.
[0026] The multifunctional medical patch for the gastrointestinal tract according to the present invention is characterized by being delivered to a target site within the gastrointestinal tract in a rolled form, wherein the rolled multifunctional medical patch for the gastrointestinal tract is rolled so that the outer layer, that is, the outer layer, becomes a therapeutic layer.
[0027] In addition, the above delivery can be made by mounting one or more multifunctional medical patches for the gastrointestinal tract in a rolled form onto a wired endoscope or a capsule endoscope and delivering them to a target site. In one embodiment of the present invention, four multifunctional medical patches for the gastrointestinal tract were mounted inside a magnetically driven capsule endoscope and delivered to a target site.
[0028] As described above, the composition of the multifunctional medical patch for the gastrointestinal tract of the present invention consists of a total of three layers, wherein the unrolling layer is made of PEGDM (polyethylene glycol dimethacrylate), the guard layer located between the unrolling layer and the medical layer is made of TEGDM (triethylene glycol dimethacrylate), and the medical layer comprises a mucosal adhesive material and a medical material.
[0029] The above mucosal adhesive material may be used, but is not limited to, one or more selected from the group consisting of chitosan, catechol, tannic acid, alginate, guar gum, xanthan gum, pectin, galactomannan, glucomannan, hyaluronic acid, glycosaminoglycans, gelatin, polyethylene glycol, polyethylene oxide, polyacrylic acid, polymethacrylic acid, polyvinylpyrrolidone, polyvinyl amine, and derivatives thereof.
[0030] The above medical material may be a drug for treating a disease or a marker / sensing material capable of monitoring an in vivo state or environment, and specifically, the above medical material may be one or more selected from the group consisting of anticancer agents, magnetic nanoparticles, hemostatic agents, tissue regeneration factors, biocompatible inks, fluorescent materials, reactive oxygen species sensing materials, and pH sensing materials, but is not limited thereto.
[0031] When a biocompatible ink or a fluorescent material is used as the medical material of the present invention, the patch of the present invention has the function of performing tattooing.
[0032] India ink and the like can be used as biocompatible inks, and rhodamine and the like can be used as fluorescent materials.
[0033] In addition, when a disease treatment drug is used as the above medical material, the drug is released from the patch of the present invention to the target site, i.e., the lesion site, within the target site in the gastrointestinal tract, thereby enabling the improvement and treatment of the disease.
[0034] In one embodiment of the present invention, anticancer activity and hemostatic activity were confirmed due to the addition of an anticancer agent and a hemostatic agent.
[0035] For example, chitosan, catechol, or epinephrine can be used as hemostatic agents, and in addition, collagen, fibrin, alginate, etc. can be used as tissue regeneration factors. When tissue regeneration factors are used together with hemostatic agents, tissue regeneration can be achieved after hemostasis.
[0036] In one embodiment of the present invention, anticancer activity was confirmed using doxorubicin (DOX) as an anticancer agent, and furthermore, it was confirmed that hyperthermia and drug release-promoting effects can also be obtained when magnetic nanoparticles (e.g., iron oxide nanoparticles) are added.
[0037] A sensing material can be used as the medical material of the present invention, for example, by using an active oxygen (ROS) sensing material / nanoparticle or a pH sensing material / nanoparticle, the condition within the gastrointestinal tract can be confirmed and analyzed.
[0038] In this case, for ROS sensing, materials such as PVP (polyvinylpyrrolidone), gold, or silica can be used, and as pH sensing materials, materials such as indium tin oxide, gold, or Wo3 can be used to observe the in vivo pH status through color changes according to pH concentration.
[0039] Next, the functional operation of the multifunctional medical patch for the gastrointestinal tract according to the present invention at the target site is described as follows.
[0040] As described above, when a rolling-type multifunctional medical patch for the gastrointestinal tract is mounted on a wired endoscope or capsule endoscope and delivered to a target site, the rolling-type multifunctional medical patch for the gastrointestinal tract, which is adhered to the surface of the target site within the gastrointestinal tract, begins to unfold as the unrolling layer located at the innermost part of the rolling shape begins to swell when the liquid within the gastrointestinal tract reaches the unrolling layer. Due to this swelling of the unrolling layer, the medical patch of the present invention is fully unfolded to conform to the curved surface within the gastrointestinal tract at the target site and is strongly adhered to the curved surface within the gastrointestinal tract by the mucosal adhesive material contained in the medical layer. Subsequently, the medical material contained in the medical layer is released to the target site, thereby exerting the intended medical action.
[0041] In addition, the present invention may provide a method for manufacturing a multifunctional medical patch for the gastrointestinal tract according to the present invention, wherein the method preferably comprises: (1) a step of manufacturing a guard layer by irradiating a TEGDM (triethylene glycol dimethacrylate) solution with ultraviolet light; (2) a step of manufacturing an unrolling layer on the guard layer manufactured in step (1) by dispensing a PEGDM (polyethylene glycol dimethacrylate) solution and irradiating ultraviolet light; (3) a step of manufacturing a therapeutic layer on the guard layer by placing the two-layer structured guard layer and unrolling layer manufactured in step (2) into a resin mold with the guard layer facing upward, pouring a mixed solution of a mucosal adhesive material and a therapeutic material over it, and then freeze-drying; and (4) a step of separating a multifunctional medical patch for the gastrointestinal tract composed of three layers, an unrolling layer, a guard layer, and a therapeutic layer, from the mold.
[0042] In addition, the multifunctional medical patch for the gastrointestinal tract separated from the mold in step (4) above may further include the step of rolling the medical layer outward into a cylindrical shape, inserting it into a cylindrical resin mold, and heating it to manufacture a rolled multifunctional medical patch for the gastrointestinal tract.
[0043] In the above method, the heating for manufacturing a rolled multifunctional medical patch for the gastrointestinal tract can be performed using a heating gun at a temperature of 150°C to 250°C for 5 to 15 seconds, and in an embodiment of the present invention, the heat treatment was performed at a temperature of 200°C for 10 seconds.
[0044] In the above method, the mucosal adhesive material may be one or more selected from the group consisting of chitosan, catechol, tannic acid, alginate, guar gum, xanthan gum, pectin, galactomannan, glucomannan, hyaluronic acid, glycosaminoglycans, gelatin, polyethylene glycol, polyethylene oxide, polyacrylic acid, polymethacrylic acid, polyvinylpyrrolidone, polyvinyl amine, and derivatives thereof.
[0045] In addition, in the above method, the medical material may be one or more selected from the group consisting of anticancer agents, magnetic nanoparticles, hemostatic agents, tissue regeneration factors, biocompatible inks, fluorescent materials, reactive oxygen species sensing materials, and pH sensing materials.
[0046] A more detailed description of the method for manufacturing a multifunctional medical patch for the gastrointestinal tract according to the present invention is provided in the following examples.
[0047] Furthermore, the inventors confirmed through experiments of the examples whether the multifunctional medical patch for the gastrointestinal tract of the present invention can be usefully used as an actual medical patch. According to one embodiment of the present invention, it was confirmed that when a patch containing a hemostatic agent is used, excellent hemostatic performance is shown in the gastrointestinal tract. Additionally, when a patch containing an anticancer agent is used, it was confirmed that it effectively kills cancer cells and exhibits excellent anticancer activity in an analysis using HT-29 human colon cancer cells. It was also confirmed that the multifunctional medical patch for the gastrointestinal tract of the present invention enables thermal resection by generating heat under an alternating magnetic field (AMF) to induce localized tissue necrosis.
[0049] The present invention will be explained in more detail below through examples. These examples are intended to explain the invention more specifically, and the scope of the invention is not limited to these examples.
[0051] <Preparation and Experimental Methods>
[0052] Production of a multifunctional medical patch for the gastrointestinal tract (TheraS)
[0053] The multifunctional medical patch for the gastrointestinal tract (TheraS) according to the present invention was manufactured to consist of three layers. First, a two-layer structure consisting of a guard layer and an unrolling layer was fabricated using ultraviolet (UV) curing (Fig. 2a). A solution of triethylene glycol dimethacrylate (TEGDM, Mw 286.3, Merck) and polyethylene glycol dimethacrylate (PEGDM, Mn 750, Merck) was prepared by mixing it with the photoinitiator 2-hydroxy-2-methylpropiophenone at a concentration of 1% v / v. To prepare the guard layer, 7 μL of TEGDM was dispensed onto a slide glass, and a silane-coated cover glass was placed on top of it. Subsequently, UV irradiation (365 nm, 230 mW cm-2) was applied for 60 seconds using an ANUJ6186 head and an ANUJ6428 lens (Panasonic Industry, Japan). After removing the cover glass, 6 μL of PEGDM solution was dispensed onto the guard layer, and a silane-coated cover glass was placed on top. Subsequently, UV irradiation (365 nm, 230 mW cm-2) was applied for 30 seconds. Finally, the cover and slide glass were removed to obtain a two-layer structure consisting of a guard layer and an unrolled layer.
[0054] The preparation process of the two-layer therapeutic layer is shown in Fig. 2b. A chitosan-catechol solution containing MNPs and DOX was prepared; specifically, 1 g of chitosan (medium molecular weight, Merck) was mixed with 5 mL of 5N HCl (Duksan, Korea) and 44.5 mL of DI water, and the pH was adjusted to 5.5. Subsequently, 1.18 g of hydrocaffeic acid (Merck) and 1.24 g of 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (Merck) were dissolved in 5 mL and 20 mL of ethanol, respectively, and the chitosan solution was added to each solution. The solutions were then dialyzed for 48 hours and 4 hours, respectively, using a 10 mM NaCl solution and DI water at pH 3.5. Afterward, the solutions were freeze-dried at -80°C. The generated chitosan-catechol base material was dissolved in 2 wt% DI water, and 1 wt% chitosan-coated MNPs and 1 mg / mL -1 DOX was added to obtain a final chitosan-catechol solution containing MNPs and DOX. The mold for fabricating the final TheraS was fabricated using a Stereolithography (SLA) 3D printer (Form3, Formlabs) with resin (Clear Resin V4, Formlabs). Next, the fabricated two-layer structure was positioned within the resin mold with the guard layer facing upward. Subsequently, the prepared chitosan-catechol solution containing MNPs and DOX was poured onto the guard layer of the two-layer structure and freeze-dried at -80°C. Afterward, the three-layer structure was separated from the resin mold to obtain the final TheraS. Additionally, for fluorescence visualization, TheraS with different fluorescent materials on each layer were fabricated using a similar process. Here, the TEGDM solution was syto9 (3 μg mL). -1 It was used mixed with Invitrogen, and the PEGDM solution was prepared using DAPI (3 μg mL) -1It was used in combination with Thermo Scientific, and the chitosan-catechol solution containing MNPs and DOX was used in combination with Rhodamine B (0.1 mg mL-1, Merck).
[0055] The process of manufacturing rolled TheraS and mounting it into a capsule is shown in Fig. 2c. The manufactured TheraS was rolled into a cylindrical shape with the treatment layer facing outward using tweezers and then inserted into a cylindrical 3D printed resin mold. To maintain the rolled state of TheraS, the TheraS inside the mold was heated at 200°C for 10 seconds using a heating gun, and subsequently, the rolled TheraS was inserted into the channels of the capsule, and finally, four rolled TheraS were prepared and placed in each capsule channel.
[0057] Morphological analysis of the gastrointestinal multifunctional medical patch (TheraS) of the present invention
[0058] The overall appearance of the unrolled and rolled states of the multifunctional medical patch for the gastrointestinal tract (TheraS) according to the present invention, and the process of TheraS unfolding in the small intestine were captured using a DSLR camera (EOS-800D, CANON). In addition, images of TheraS and fluorescently labeled cross-sections were captured and analyzed using a FE-SEM (SU8020, Hitachi) and a confocal microscope (FV1200, Olympus) at the Institute of Advanced Semiconductor Technology (INST) at DGIST.
[0060] FT-IR Spectral Analysis of the Multifunctional Medical Patch for the Gastrointestinal Tract (TheraS) of the Present Invention
[0061] To confirm the chemical composition of the multifunctional medical patch for the gastrointestinal tract (TheraS) according to the present invention, FT-IR spectra were analyzed using an ATR-FT-IR microscope (Nicolet Continuum, Thermo Scientific) at DGIST INST. Individual layers were prepared to investigate the chemical composition of each TheraS layer. First, to fabricate a single unwinding layer, 6 μL of PEGDM solution was dispensed onto a slide glass, and a silane-coated cover glass was placed on top. Subsequently, UV irradiation (365 nm, 230 mW cm⁻¹) was applied. -2 A single PEGDM layer was created by applying ) for 60 seconds. Next, a single guard layer was prepared by irradiating the TEGDM solution with UV light for 30 seconds. Finally, a chitosan-catechol solution containing MNPs and DOX was poured into a resin mold and freeze-dried at -80°C to prepare a therapeutic layer. FT-IR spectra were analyzed for each of the prepared individual layers.
[0063] Adhesion analysis
[0064] The adhesive force between the gastrointestinal multifunctional medical patch (TheraS) of the present invention and a pig small intestine (BIOZOA Biological Supply, Korea) was analyzed using an electric stage (KZL06050-N1-FD, Suruga Seiki, Japan) and a load cell (DBCM-5, Bongshin, Korea). To this end, the load cell was first fixed on top, and the pig small intestine was fixed to the electric stage. Next, the unfolded TheraS, connected to the load cell by a string, was placed on the surface of the pig intestine. After contact at regular intervals, the stage was moved downward at a constant speed to measure the adhesive force applied to the load cell. The LabVIEW program (National Instruments, USA) was used to record the force measurements. In addition, an experiment was conducted to compare the adhesive strength of TheraS of the present invention in the porcine small intestine with the adhesive strength of gelatin sheets widely used for drug delivery. For the gelatin sheets, a 10% gelatin (bovine skin, Deoksan, Korea) solution was poured into a 35 mm dish and dried overnight. To obtain the final gelatin sheets, the dried gelatin was cut to the same size as TheraS, and the size of the cuts can be adjusted to the desired size as needed. TheraS and a gelatin sheet were placed in contact with the surface of the pig small intestine for 60 and 120 seconds, respectively. The adhesion between the small intestine and the sheet was measured as the motorized stage moved downward. This measurement was repeated for 10 sets. Measurements were also performed on the adhesion between the pig stomach (BIOZOA Biological Supply, Korea) and the sheet.
[0066] Analysis of temperature change of the gastrointestinal multifunctional medical patch (TheraS) of the present invention under alternating magnetic field (AMF)
[0067] The temperature change of the patch of the present invention was measured under an alternating magnetic field. To this end, TheraS was immersed in phosphate-buffered saline (PBS) and an alternating magnetic field (320 A, 325 kHz) was applied for 20 minutes. The temperature change of TheraS was measured and recorded every 2 minutes using a thermal imaging camera (GTC 400 C, BOSCH), and measurements were performed under two different initial temperature conditions: room temperature (RT, 16.5°C) and body temperature (BT, 37.0°C). In addition, for each initial condition, the temperature change was measured by repeating the process 5 times during exposure to the alternating magnetic field.
[0069] Drug release analysis of the gastrointestinal multifunctional medical patch (TheraS) of the present invention
[0070] To visually confirm the drug release process of TheraS of the present invention, TheraS containing the model drug Rhodamine was placed on the surface of the small intestine of pigs. Assuming that TheraS is in a unfolded state, an unfolded sheet was placed on the small intestine. TheraS was detached after 2, 4, 6, 8, and 10 minutes of contact, and Rhodamine released onto the surface of the pig small intestine was observed using a DSLR camera. The experiment was performed with and without the application of AMF (320 A, 325 kHz) for the first 2 minutes. In addition, the area of Rhodamine released onto the surface of the small intestine was quantitatively measured using ImageJ software (National Institutes of Health, USA). Each experiment was repeated three times.
[0071] In addition, to evaluate the amount of DOX released from TheraS of the present invention, the amount of DOX loaded on TheraS before and after contact with the surface of the porcine small intestine was evaluated. After contacting the original TheraS and the separated TheraS with the surface of the small intestine, they were completely dissolved in a shaking incubator (JSSI-100C, JSR, Korea) at 50°C and 300 rpm for 2 minutes after 2, 4, 6, 8, and 10 minutes. The concentration of DOX dissolved in the original solution and the solution of the separated TheraS was measured at 490 nm using a UV-vis spectrophotometer (SPECTROstar Nano, BMG LABTECH). The amount of DOX delivered to the surface of the porcine small intestine via TheraS was quantitatively measured using a drug release test, and each experiment was repeated 5 times.
[0073] Unrolling test in a pig stomach
[0074] To evaluate the unrolling performance of TheraS of the present invention, unrolling motion tests were performed on cross-sections of pig stomachs with various curvatures. Four sections of pig stomachs with different curvatures were prepared, and rolling TheraS loaded with Rhodamine was placed on the wet stomach surface. The process of spreading and adhering TheraS to the stomach surface was recorded using a DSLR camera. After completely spreading TheraS on the pig stomach surface, it was maintained for 10 minutes and then separated. A plan view of the stomach sample showing the drug released from TheraS was observed using a DSLR camera. A cross-sectional view of the pig stomach sample was also observed. Additionally, the stomach sample was frozen with an OCT compound in Cryomold, and the frozen sample was sliced into 100 μm sections using a cryostat microtome (Leica / CM3050S) at DGIST INST. The thinly sliced cross-sections were placed on glass slides and imaged and analyzed using a confocal microscope (LSM900, Carl Zeiss) at DGIST INST.
[0076] Magnetically driven capsule for delivering the gastrointestinal multifunctional medical patch (TheraS) of the present invention
[0077] The magnetically actuated capsule designed to deliver the TheraS of the present invention to a target lesion site was constructed using an Ecoflex lid assembly. It was configured to consist of four deployable TheraS; a capsule camera, a rod, a body, and a head; a pushing bar; metal pins; and permanent magnets. Additionally, the center rod, the capsule body, and the pushing bar were fabricated using an SLA 3D printer containing transparent resin. The permanent magnet attached to the pushing bar consists of two axially magnetized ring-shaped magnets (MAGNA, Japan) with inner diameters, outer diameters, and heights of 2.5 mm, 8 mm, and 2.5 mm, respectively, and one radially magnetized ring-shaped magnet (JLMAGNET, Korea), with inner diameters, outer diameters, and heights of 2.3 mm, 8 mm, and 1 mm, respectively. Two hemispherical metal pins with a diameter of 1.5 mm (Nailmall, Korea) were attached to the pushing bar. The Ecoflex lid assembly was prepared by pouring Ecoflex 00-30 (Smooth-On Inc, USA) mixed with a lipophilic blue dye into a resin mold and drying it at 60°C for 2 hours. The resin mold was fabricated using an SLA 3D printer and silane coated after 60 minutes of UV exposure (405 nm, 9.1 W) and 120 minutes of heat treatment (120°C). To image the inside of the gastrointestinal tract, a wired capsule camera (OV6946 endoscope module, Dothecamera) with a diameter of 2 mm and a height of 4 mm was used. The camera was assembled in the center of the channel entrance, and the wire passed through the central rod and exited the capsule head.
[0079] In vitro delivery test of the present invention's multifunctional medical patch for the gastrointestinal tract (TheraS).
[0080] In vitro tests were performed using a magnetically actuated capsule to verify whether TheraS of the present invention is delivered to the pig stomach and small intestine. The magnetically actuated capsule was moved via an EMA system to deliver the mounted TheraS. First, a pig stomach was placed on a 3D-printed stomach-shaped test bed. Next, the capsule moved to the target lesion location during the movement mode, and subsequently, during the sheet delivery mode, the capsule extruded and deployed TheraS. During this process, TheraS was extruded from the lower channel closest to the stomach surface using a uniform field applied at an oblique angle downward. By repeating this process, four TheraS contained in the capsule were delivered to specific locations on the pig stomach. Additionally, the deployment of the delivered TheraS was simultaneously recorded using a DSLR and a capsule camera, and experiments on the pig small intestine fixed to a 3D-printed small intestine-shaped phantom were performed in the same manner.
[0082] Analysis of the hemostatic performance of the gastrointestinal multifunctional medical patch (TheraS) of the present invention
[0083] To evaluate the hemostatic performance of TheraS of the present invention, whole blood coagulation tests and platelet adhesion tests were performed. For this purpose, 0.2 mL of human citrate-added blood was poured into TheraS, and 20 μL of 0.2 M CaCl2 was added for blood coagulation. Subsequently, the samples were incubated at 30 rpm at a temperature of 37°C for 0, 2, 4, 6, 8, and 10 minutes. Afterward, the samples were hemolyzed using 20 mL of DI water, and the absorbance was measured at 540 nm using a UV-vis spectrophotometer. The hemostatic performance of control blood, gelatin sheets, and gelatin-chitosan sheets was processed and compared using the same procedure. Gelatin-chitosan microneedle patches were prepared by the following method: a solution containing 10% gelatin (bovine skin, Deoksan, Korea) and 2% chitosan (medium molecular weight, 75–85% deacetylated) in a 2:1 ratio was poured into a 35 mm dish and dried overnight. The dried gelatin-chitosan sheets were cut to the same size (7 × 10 mm) as TheraS, and each experiment was repeated 5 times.
[0084] In addition, to perform the platelet adhesion test, citric acid-added blood was centrifuged at 2500 rpm for 5 minutes to obtain platelet-rich plasma (PRP), and subsequently, 100 μL of PRP was added to TheraS and incubated at 37 °C for 20 minutes. The samples were washed three times with PBS and fixed with a 0.1% glutaraldehyde solution for 2 hours. Afterward, the samples were dried to obtain SEM images. Similarly, to compare platelet adhesion, gelatin and gelatin-chitosan sheets were treated using the same process.
[0086] Cytotoxicity test of the gastrointestinal multifunctional medical patch (TheraS) of the present invention on HT-29 cells
[0087] The anticancer efficacy of TheraS of the present invention was evaluated in HT-29 cells (human colorectal cancer cell line, ATCC, USA). HT-29 cells were cultured in RPMI 1640 medium (Gibco) containing 10% fetal bovine serum (Gibco) and 1% penicillin-streptomycin (Gibco), seeded at a density of 1×10^6 cells per 35 mm cell culture dish, and counted using Cell Count Kit-8 (CCK-8). Before administering TheraS, cells were cultured for 24 hours under 5% CO2 conditions. For each experimental group, five sets of cell viability experiments were performed as follows: a control group, TheraS without MNPs and DOX (TheraS(MNPs- and DOX-)), TheraS without DOX with or without AMF (TheraS(DOX-)), and TheraS with or without AMF. In addition, the AMF-treated group was exposed to AMF (320 A, 325 kHz) for 10 minutes. After exposure to each experimental condition for 24 hours, the cell viability of each group was analyzed. Additionally, the nuclei of living cells were stained with DAPI, and fluorescence images of the cells were obtained using a fluorescence microscope (LSM700, Zeiss). The total cell viability of each experimental group was measured at 450 nm using CCK-8 assay, and statistical significance for each group was analyzed using p-tests and one-way ANOVA, with results of p<0.005 considered significant.
[0089] Thermal resection using the multifunctional medical patch (TheraS) for the gastrointestinal tract of the present invention
[0090] The thermal resection performance evaluation of TheraS of the present invention was analyzed using samples of the small intestine and stomach of pigs. First, TheraS was fully spread out and placed in the pig intestine, and then treated with AMF (320 A, 325 kHz). After 40 minutes of AMF application, TheraS was separated from the surface of the pig intestine, and the heat-treated surface of the small intestine was observed using a DSLR camera. Subsequently, the spread-out TheraS was placed in the pig stomach and AMF was applied for 40 minutes. After removing TheraS, the surface of the stomach was observed using a DSLR camera.
[0091] In addition, histological analysis was performed on the surface of the porcine small intestine that had undergone thermal resection using TheraS. Heat-treated intestinal sections were stained with hematoxylin and eosin (H&E). Specifically, the heat-treated intestinal specimens were fixed using a formaldehyde solution, dehydrated with ethanol and xylene, and then embedded in paraffin. The resulting tissue-embedded paraffin blocks were sliced into 4 μm thick slices using a rotary microtome (RM2255, Leica, Germany) at the INST of DGIST. Each section was placed on a glass slide, paraffin was removed with xylene, and then dehydrated with ethanol. Subsequently, the sections were stained with H&E for 10 minutes and 2 minutes, respectively, washed with ethanol and xylene, and dried. For histological analysis, each treated section was observed using a fluorescence microscope (Nikon-Eclipse-90i). Paraffin blocks of thermally removed gastric tissue intestinal tissue were prepared using a similar method, and paraffin sections were prepared. Each section was stained with H&E, and histological analysis was performed using a fluorescence microscope.
[0093] Statistical analysis
[0094] All statistical data analysis was performed using Microsoft Excel, and data were presented as mean ± standard deviation (SD) from at least three independent experiments. Statistical significance for each experimental group was analyzed using p-tests and one-way analysis of variance (ANOVA), and cases marked with "*" or "**" when p<0.005 or p<0.0005 were considered statistically significant.
[0096] <Example 1>
[0097] Manufacturing and Characterization of the Gastrointestinal Multifunctional Medical Patch (TheraS) of the Present Invention
[0098] TheraS devised in this invention was prepared by sequentially UV curing TEGDM and PEGDM solutions, followed by pouring a chitosan-catechol solution containing MNPs and DOX and freeze-drying (Figs. 2a and 2b). Subsequently, the prepared TheraS was rolled up and mounted in the proposed capsule (Fig. 2c). The PEGDM and TEGDM used in TheraS of this invention are bioinert materials that can be easily produced in various shapes through UV curing; furthermore, photopolymerized PEGDM swells upon contact with liquid, making it suitable for delivering drugs to curved surfaces such as the eye. Additionally, the chitosan-catechol used as the therapeutic layer is a key material for mussel adhesion, possessing excellent adhesive properties even in humid environments, as well as high strength, high rigidity, and water resistance.
[0099] Furthermore, due to its biodegradability, chitosan-catechol binds strongly to gastrointestinal surface mucus and dissolves in the gastrointestinal tract after treatment. Due to its excellent hemostatic performance, chitosan-catechol can also be used for hemostatic therapy. MNPs loaded into the therapeutic layer were coated with chitosan to ensure biocompatibility.
[0100] Furthermore, the characteristics of TheraS according to the present invention were analyzed. The elemental distribution of TheraS according to the present invention was observed using energy dispersive X-ray spectroscopy (EDS, SU8020, Hitachi), and as a result, Fe mapping confirmed that the chitosan-coated MNPs were uniformly distributed in the treatment layer. The magnetization values (M) of the chitosan-coated MNPs and TheraS were analyzed using a vibration sampling magnetometer (VSM, Model 7407, Lake Shore Cryotronics), and as a result, they were approximately 84.25 emu / g and 3.74 emu / g, respectively.
[0101] In addition, images of the unfolded and rolled states of TheraS of the present invention were confirmed using a digital single-lens reflex (DSLR) camera (EOS-800D, CANON) as shown in FIG. 3a and 3b, respectively. A cross-sectional image of TheraS was obtained using a field emission scanning electron microscope (FE-SEM) as shown in FIG. 3c.
[0102] As a result of observation, the size of the unfolded TheraS was 10×7 mm, and the thicknesses of the unrolled layer, guard layer, and therapeutic layer were confirmed to be approximately 16 μm, 8 μm, and 0.7 mm, respectively. In addition, cross-sectional fluorescence images of TheraS prepared using a PEGDM solution containing 4',6-diamidino-2-phenylindole (DAPI), a TEGDM solution containing syto9, and a chitosan-catechol solution containing DOX containing MNPs and Rhodamine B were observed using a confocal microscope (Fig. 3d).
[0103] In addition, the process of TheraS unfolding after being delivered to the surface of the small intestine was observed and illustrated in Fig. 3e. First, rolled TheraS was placed on the wet surface of the small intestine, and it was found that when the mucus of the small intestine (pH 6.8) reached the unrolled layer of TheraS, the layer began to swell, followed by bending and stress relief, and the unfolding, or unrolling, of TheraS began. Subsequently, it was found to gradually and eventually completely unravel and adhere to the surface of the small intestine. Furthermore, the unfolding process of TheraS was confirmed in a porcine small intestine (pH 8.0) using artificial intestinal fluid (pH 8.0) and a porcine stomach (pH 2.0) using artificial gastric fluid (pH 2.0).
[0104] As a result, it was confirmed that TheraS of the present invention unfolds after being placed on the surface of various gastrointestinal environments having various pH values (small intestine: pH 6.6-8.0, large intestine: pH 6.5, and stomach: pH 1-2.5).
[0105] In addition, it was confirmed that TheraS of the present invention exhibits excellent adhesion to the surface of the gastrointestinal tract, and this adhesive performance was found to be superior to that of gelatin sheets.
[0107] <Example 2>
[0108] Confirmation of drug release of the gastrointestinal multifunctional medical patch of the present invention in an alternating magnetic field (AMF).
[0109] To evaluate the drug release profile on the gastrointestinal surface for the gastrointestinal multifunctional medical patch (TheraS) of the present invention, TheraS loaded with Rhodamine was placed on the surface of the small intestine of pigs for a specific period, then detached, and the profile on the gastrointestinal surface was analyzed. The drug release profile of TheraS was observed for a group that applied AMF for an initial 2 minutes and a group that did not.
[0110] As a result, as shown in Fig. 4a, the drug release area of TheraS increased with contact time in both the group with and without AMF, and in particular, the group with AMF showed a larger drug release area compared to the group without. In addition, the drug release area of TheraS delivered to the surface of the pig small intestine was measured using ImageJ software. When TheraS was contacted with the surface of the pig small intestine for 10 minutes, the drug was released to approximately 75.68% and 95.85% of the total surface area of TheraS in the group without and with AMF, respectively (Fig. 4b). Through this, the inventors found that applying AMF can further enhance drug release from TheraS of the present invention, thereby increasing the amount of drug delivered to the surface of the gastrointestinal tract.
[0111] In addition, to measure the release of the DOX drug from the TheraS of the present invention, the unfolded TheraS was brought into contact with the surface of the pig small intestine for a specific period and then separated. Subsequently, the amount of DOX remaining in TheraS was measured using a UV-vis spectrophotometer after completely dissolving the TheraS before and after contact with the surface of the pig small intestine in DI water. The amount of DOX delivered to the pig small intestine was calculated by subtracting the amount of DOX remaining in TheraS after drug delivery from the amount originally loaded in TheraS.
[0112] As a result, when TheraS was in contact with the surface of the porcine small intestine for 10 minutes, approximately 46.63% and 61.05% of DOX were released from TheraS in the group without AMF application and the group with AMF application, respectively (Fig. 4c). Therefore, these results also indicate that the application of AMF can enhance the release level of the drug from TheraS and ultimately induce greater drug delivery to the surface of the gastrointestinal tract.
[0114] <Example 3>
[0115] Analysis of delivery efficacy of the gastrointestinal multifunctional medical patch of the present invention in vitro
[0116] Next, the inventors performed an in vitro test using a pig stomach to verify targeted delivery using a capsule, in order to confirm whether the gastrointestinal multifunctional medical patch (TheraS) of the present invention can move to a desired location and deliver TheraS via magnetic operation. To this end, a pig stomach was first attached to a three-dimensional (3D) printed phantom, and a magnetically driven capsule was actuated using an EMA system (Fig. 5a).
[0117] As a result, the capsule was moved to the target lesion site by an external magnetic field, the TheraS equipped with a pushing bar was pushed, the Ecoflex lid assembly folded, the capsule channel opened and TheraS was released, and the remaining three TheraS were successfully delivered into the pig's stomach likewise (Fig. 5b).
[0118] In addition, the inventors used a camera mounted on the capsule during the in vitro analysis process to record images of the stomach surface to which the TheraS of the present invention was delivered in real time, as shown in FIGS. 5c to 5f. By confirming that each TheraS gradually unwraps and attaches to the stomach surface after being delivered to the target site, it was confirmed that delivery of multiple TheraS to multiple target sites is possible.
[0120] <Example 4>
[0121] Analysis of the hemostatic performance of the multifunctional medical patch for the gastrointestinal tract of the present invention
[0122] Gastrointestinal bleeding refers to bleeding caused by damage to the mucous membranes of organs such as the esophagus, stomach, small intestine, and colon, and is known to occur due to peptic ulcers, polypectomy, colorectal cancer, etc. Accordingly, the inventors performed whole blood coagulation tests and platelet adhesion experiments to analyze the hemostatic performance of TheraS of the present invention. To this end, whole blood coagulation tests were performed on a total of four groups: control blood, gelatin sheet, gelatin-chitosan sheet, and the group treated with TheraS of the present invention.
[0123] As a result, it was found that the longer whole blood was applied to each experimental group, the more blood clots formed on the surface of each sample, leading to increased capture of red blood cells. Conversely, when deionized water (DI water) was added, samples with severe coagulation showed reduced hemolysis and exhibited brighter colors (Fig. 6a). In particular, in the group treated with TheraS of the present invention, significant blood coagulation was observed when exposed to whole blood for more than 4 minutes. This blood coagulation was found to be faster and more effective in the group treated with TheraS of the present invention compared to other experimental groups.
[0124] In addition, hemoglobin absorbance was measured at 540 nm using a UV-vis spectrophotometer, and a lower absorbance indicates a higher coagulation rate.
[0125] As a result of the analysis, as shown in Fig. 6b, the optical density (OD) values of the control blood, gelatin sheet, gelatin-chitosan sheet, and TheraS treatment group were found to be 1.428, 1.039, 0.407, and 0.077, respectively, after 10 minutes of sample application. This confirmed that TheraS of the present invention has a significantly superior blood coagulation effect compared to other experimental groups, and the appearance of the hemolyzed blood after coagulation for each experimental group is shown in Fig. 6c.
[0127] In addition, a platelet adhesion test was performed to observe the tendency of platelets to adhere to the surface of TheraS of the present invention. For this purpose, the test was conducted on three experimental groups: a gelatin sheet, a gelatin-chitosan sheet, and a TheraS-treated group, and platelet aggregation in each group was observed using SEM.
[0128] As a result, as shown in Fig. 6d, it was confirmed that a larger number of platelets were attached to TheraS of the present invention than to gelatin and gelatin-chitosan sheets.
[0130] Through this, it was found that the multifunctional medical patch for the gastrointestinal tract of the present invention contains chitosan-catechol in the therapeutic layer, thereby promoting red blood cell coagulation and platelet activation to rapidly induce hemostasis, and thus exhibiting excellent hemostatic performance. Therefore, it was found that the multifunctional medical patch for the gastrointestinal tract of the present invention can be effectively used for the treatment of gastrointestinal bleeding.
[0132] <Example 5>
[0133] Analysis of the cancer treatment effect of the multifunctional medical patch for the gastrointestinal tract of the present invention
[0134] Furthermore, the inventors conducted a cytotoxicity test using HT-29 human colorectal cancer cells to confirm whether the gastrointestinal multifunctional medical patch (TheraS) of the present invention has therapeutic efficacy against cancer. To this end, cells were cultured in a cell culture plate and treated with TheraS of the present invention for 24 hours. Cell viability was evaluated in a total of six experimental groups, including a control group, TheraS without MNPs and DOX (TheraS(MNPs- and DOX-)), TheraS without DOX (TheraS(DOX-) with or without AMF), and TheraS treatment groups with or without AMF applied.
[0135] For the analysis, the nuclei of cells from each experimental group were stained with DAPI and observed under a fluorescence microscope.
[0136] As a result, as shown in Figures 7a-7f, TheraS without MNPs and DOX did not significantly affect cell viability due to the biocompatibility of chitosan-catechol and the bioinactive properties of PEGDM and TEGDM in the treatment layer. In TheraS(DOX-) without an alternating magnetic field (AMF), a small number of cell deaths were observed due to the chitosan-coated MNPs. TheraS(DOX-) with AMF showed a greater number of induced cell deaths, confirming that the TheraS of the present invention with AMF can effectively kill cancer cells by inducing high heat. Additionally, it was confirmed that the TheraS group without AMF showed a significant number of cell deaths due to the release of the DOX drug. Furthermore, it was found that the TheraS group with AMF induced high heat and simultaneously released DOX under AMF conditions, indicating that TheraS could induce the most extensive and effective death of cancer cells.
[0137] Regarding the experimental results described above, the cell viability of each experimental group was quantitatively analyzed using CCK-8 analysis. As shown in Figure 7g, the TheraS (MNPs- and DOX-) treated group showed a cell viability of approximately 94.96%, which appears to indicate minimal cytotoxicity due to the absence of MNPs and DOX. The TheraS (DOX-) treated group without AMF application showed a cell viability of approximately 73.94%, which suggests that the chitosan-coated MNPs influenced the inhibition of cell growth. In contrast, the TheraS (DOX-) treated group with AMF application showed a cell viability of approximately 42.94%, which appears to indicate that tumor cell death was induced by high heat under AMF. The TheraS treated group without AMF application showed a cell viability of approximately 48.03%, which appears to be due to the released drug, DOX. Furthermore, the TheraS treatment group with AMF showed a cell survival rate of approximately 35.37%, exhibiting the most superior anticancer efficacy. This was because effective induction of cancer cell death occurred through the release of DOX drugs along with the induction of high heat under AMF conditions.
[0139] <Example 6>
[0140] Analysis of the feasibility of thermal ablation using the multifunctional medical patch for the gastrointestinal tract of the present invention under alternating magnetic fields (AMF).
[0141] The inventors performed thermal resection to evaluate the thermal resection capability of the gastrointestinal multifunctional medical patch (TheraS) of the present invention. The experiment was conducted by placing TheraS spread on the surface of the small intestine of a pig to which AMF was applied. After TheraS was unrolled, AMF was applied for 40 minutes, then TheraS was removed, and the surface of the small intestine was observed.
[0142] The area heated by TheraS under AMF showed a distinct distinction from the normal tissue (NT) area on the surface of the intestine (Figs. 8a and 8b). The white areas on the surface of the pig intestine represent areas of coagulated necrosis (CN), which is a well-known phenomenon observed in tissues exposed to temperatures above 50°C.
[0143] The results of performing thermal resection on a pig stomach using TheraS of the present invention under AMF are shown in Figures 8c and 8d. It was observed that tissue necrosis occurred on the surface of the pig stomach to which TheraS was delivered due to the heat generated by TheraS under AMF, and the resected area turned brown, unlike the pig small intestine.
[0144] In addition, the thermal resection ability of TheraS in the porcine small intestine was analyzed using hematoxylin and eosin (H&E) staining. As shown in Fig. 8e, the CN region appeared brighter than the NT region, indicating that thermal resection occurred on the intestinal surface as TheraS was delivered and heat was generated under AMF. Similarly, a clear distinction between the normal and necrotic regions was observed in the thermally resected porcine stomach area (Fig. 8f). In particular, since tissues may boil or carbonize at temperatures above 100°C, it is appropriate to perform thermal resection within a temperature range of 50 to 100°C. Accordingly, in the present invention, TheraS was applied under AMF, and the temperature was gradually increased from an initial temperature of 37°C to approximately 60°C within 40 minutes, which implies that appropriate thermal resection is possible in the target area.
[0145] Through these results, the inventors found that the multifunctional medical patch for the gastrointestinal tract of the present invention can be usefully employed in the treatment of cancer or tumors, as it enables thermal resection by generating heat under AMF to induce localized tissue necrosis.
[0147] Those skilled in the art to which the present invention pertains will understand that the present invention may be embodied in modified forms without departing from the essential characteristics of the invention. Therefore, the disclosed embodiments should be considered in an illustrative rather than a restrictive sense. The scope of the invention is defined by the claims, not by the foregoing description, and all variations within the scope of equivalents should be interpreted as being included in the invention.
Claims
Claim 1 A multifunctional medical patch for the gastrointestinal tract composed of three layers: an unrolling layer, a guard layer, and a therapeutic layer, wherein the unrolling layer is composed of PEGDM (polyethylene glycol dimethacrylate) and undergoes swelling upon contact with liquid at the target site, the guard layer is located between the unrolling layer and the therapeutic layer and is composed of TEGDM (triethylene glycol dimethacrylate), and the therapeutic layer comprises a mucosal adhesive material and a medical material and is characterized by adhering to the target site, wherein the multifunctional medical patch for the gastrointestinal tract is mounted on a wired endoscope or capsule endoscope in a rolled form, delivered to a target site within the gastrointestinal tract for adhesion, wherein the outer layer in the rolled form is the therapeutic layer, and as the unrolling layer swells due to liquid within the gastrointestinal tract, it fully unfolds to conform to the curved surface of the target site, adheres strongly by the mucosal adhesive material contained in the therapeutic layer, and the medical material is released to the target site. Multifunctional medical patch. Claim 2 delete Claim 3 delete Claim 4 delete Claim 5 A multifunctional medical patch for the gastrointestinal tract according to claim 1, wherein the mucosal adhesive material is one or more selected from the group consisting of chitosan, catechol, tannic acid, alginate, guar gum, xanthan gum, pectin, galactomannan, glucomannan, hyaluronic acid, glycosaminoglycans, gelatin, polyethylene glycol, polyethylene oxide, polyacrylic acid, polymethacrylic acid, polyvinylpyrrolidone, and polyvinyl amine. Claim 6 A multifunctional medical patch for the gastrointestinal tract according to claim 1, wherein the medical material is one or more selected from the group consisting of anticancer agents, magnetic nanoparticles, hemostatic agents, tissue regeneration factors, biocompatible ink, fluorescent materials, reactive oxygen species sensing materials, and pH sensing materials. Claim 7 delete Claim 8 (1) a step of preparing a guard layer by irradiating a TEGDM (triethylene glycol dimethacrylate) solution with ultraviolet light; (2) a step of preparing an unrolling layer on the guard layer prepared in step (1) by dispensing a PEGDM (polyethylene glycol dimethacrylate) solution and irradiating it with ultraviolet light; (3) a step of preparing a therapeutic layer on the guard layer by placing the two-layer structured guard layer and unrolling layer prepared in step (2) into a resin mold with the guard layer facing upward, pouring a mixed solution of a mucosal adhesive material and a medical material over it, and then freeze-drying; (4) a step of separating a multifunctional medical patch for the gastrointestinal tract composed of three layers—an unrolling layer, a guard layer, and a therapeutic layer—from the mold; A method for manufacturing a multifunctional medical patch for gastrointestinal tract, comprising the step of (5) separating the multifunctional medical patch for gastrointestinal tract from the mold in step (4) into a cylindrical shape with the medical layer facing outward, then inserting it into a cylindrical resin mold and heating it to produce a rolled multifunctional medical patch for gastrointestinal tract, wherein the heating is performed using a heating gun at a temperature of 150°C to 250°C for 5 to 15 seconds. Claim 9 delete Claim 10 delete Claim 11 A method for manufacturing a multifunctional medical patch for the gastrointestinal tract according to claim 8, wherein the mucosal adhesive material is one or more selected from the group consisting of chitosan, catechol, tannic acid, alginate, guar gum, xanthan gum, pectin, galactomannan, glucomannan, hyaluronic acid, glycosaminoglycans, gelatin, polyethylene glycol, polyethylene oxide, polyacrylic acid, polymethacrylic acid, polyvinylpyrrolidone, and polyvinyl amine. Claim 12 A method for manufacturing a multifunctional medical patch for the gastrointestinal tract according to claim 8, wherein the medical material is one or more selected from the group consisting of anticancer agents, magnetic nanoparticles, hemostatic agents, tissue regeneration factors, biocompatible ink, fluorescent materials, reactive oxygen species sensing materials, and pH sensing materials.
Citation Information
Patent Citations
Expansion controllable medicine sustained-release sheet utilizing four layered structure
JP2020156968A
Therapeutic patch for gastrointestinal tract and manufacturing method thereof
KR1020230056347A
